Paris, France and Camberley, UK – 12 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 11 March 2021 that, as at 10 March 2021, BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.99% (2,117,183 shares). http://novacyt.com/wp-content/uploads/2021/03/Novacyt-BlackRock-holdings-12.03.2021-ENGLISH.pdf
Visit PageNews and Events
Correction: Research and Development Update
This is a correction to the Research and Development Update announcement published at 7:00am on 24 February 2021 (RNS number 1141Q) which has been amended with the following underlined additions to make it consistent with the French announcement released on Euronext at 8am CET on 24 February 2021. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-RD-Update-24.02.2021-correction-ENGLISH.pdf
Visit PagePoint sur la Recherche & Développement
Paris, France et Camberley, Royaume-Uni – 24 février 2021 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur l’avancement de ses programmes de recherche et développement (R&D) en cours, y compris le développement de son portefeuille de produits, les essais cliniques et la publication des validations
Visit Page